Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
About this item
Full title
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2019-01, Vol.380 (1), p.11-22
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this multicenter, placebo-controlled trial involving statin-treated patients with hypertriglyceridemia, the risk of ischemic events, including cardiovascular death, was significantly lower with 2 g of icosapent ethyl twice daily than with placebo.
Alternative Titles
Full title
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2132248226
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2132248226
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1812792
